Overview

Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)

Status:
Completed

Trial end date:
2016-01-20

Target enrollment:

Participant gender:

Summary

The intent of this study is to describe the safety and efficacy of daptomycin versus standard of care (SOC) in pediatric participants aged 1-17 years with bacteremia caused by Staphylococcus aureus (S. aureus).

Phase:

Phase 4

Details

Lead Sponsor:

Cubist Pharmaceuticals LLC

Treatments:

Cephalosporins
Clindamycin
Daptomycin
Penicillins
Vancomycin